BNET Industries

Antares Pharma Inc.

(AIS) is in the Health Care Industry

Market Cap:$93.1M

Last Fiscal Year Sales:$7.8M

Public
US

Dow Jones Description

Antares Pharma, Inc. (?Antares? or the ?Company?) is a specialty drug delivery/pharmaceutical company utilizing its experience and expertise in drug delivery systems to enhance the performance of established and developing pharmaceuticals. The Company currently has three primary delivery platforms (1) transdermal gels, (2) fast-melt tablets, and (3) injection devices. These technologies are summarized and briefly described below. Technology Platforms [[Image Removed]] Transdermal Drug Delivery Antares? transdermal drug delivery platform is dedicated to developing gels that offer a cosmetically superior option to patches, while delivering medication efficiently with less potential for skin irritation and avoiding the initial gastrointestinal and liver uptake problems of some orally ingested drugs. The Company?s gels consist of a hydro-alcoholic gel containing a combination of permeation enhancers to promote rapid drug absorption through the skin following application to the arms, shoulders, or abdomen.

President & Chief Executive Officer

Paul K Wotton PhD

Number of Employees 33

Contact Information

250 Phillips Blvd

Suite 290

Ewing, New Jersey 08618

www.antaresphar...

609-359-3020

Peer Companies

NAICS Code Surgical and Medical Instrument Manufacturing: 339112

Recent Events

Ferring International to acquire assets of Antares Pharma

11/13/09 - Merger / Acquisition - View Story
Antares Pharma Inks Licensing and Asset Purchase Pact with Ferring

11/17/09 - Joint Venture / Alliance - View Story
Antares Pharma, Inc. ANTR Enters into License and Asset Purchase Agreements with Ferring; Majority of...

11/11/09 - Joint Venture / Alliance - View Story
Antares Pharma Reports Third Quarter 2009 Financial and Operating Results

11/09/09 - Financial Announcement - View Story
Company and People Notes: Merck and Portola Sign Agreement; Eisai Appoints Senior Vice-Presidents; More ...

8/26/09 - Mgmt. Change Entering - CFO - View Story
Antares Pharma Q2 net loss narrows

8/14/09 - Financial Announcement - View Story
BUYINS.NET: BXC, AIS, SENO, DISK, ROIA Expected To Be Lower Leading Up To Next Earnings...

7/30/09 - Joint Venture / Alliance - View Story
Francis Collins to head NIH

7/15/09 - Mgmt. Change Entering - CFO - View Story
Antares Pharma Promoted Robert Apple To EVP, CFO And President Of Parental Products Division -...

7/08/09 - Mgmt. Change Entering - President - View Story
Antares Pharma Promotes Robert F. Apple, Dr. Kaushik Dave and Dr. Peter Sadowski

7/08/09 - Mgmt. Change Entering - CFO - View Story

News & Analysis

Filter by

Sort Type
Related Tags

antares pharma inc. - All News and Analysis

Antares Receives a Notice of Allowance for U.S. Patent Covering Anturol

- 2008-06-04

EWING, N.J. -- Antares Pharma, Inc. (AMEX:AIS) a specialty pharmaceutical company, today reported that the United States Patent & Trademark Office USPTO has issued a Notice of Allowance for U. S. patent application 11/120,306 entitled "Permeation Enhancing Compositions For Anticholinergic Agents" related to Antares' Anturol[TM] product for the treatment of...

Tags: Antares Pharma Inc., Company, U.S. Patent and Trademark Office
Antares Pharma Announces Notice of Allowance for Newest ATD Gel Patent

- 2007-02-21

EWING, N.J. -- Antares Pharma, Inc. (Amex:AIS) announced receipt of Notice of Allowance from the United States Patent & Trademark Office USPTO covering semi-solid pharmaceutical compositions used in its Advanced Transdermal Delivery (ATD[TM]) technology. The USPTO has stated that it intends to grant patent protection which covers hormonal and non-hormonal...

Tags: Antares Pharma Inc., U.S. Patent and Trademark Office
Antares Pharma Announces Notice of Allowance for Elestrin Patent by U.S. Patent & Trademark Office

- 2007-02-07

EWING, N.J. -- Antares Pharma, Inc. (Amex: AIS) announced receipt of notice of allowance from the United States Patent & Trademark Office USPTO covering the formulation used in Elestrin[TM] estradiol gel which was co-invented by Antares and our licensee, BioSante. The USPTO has stated that it intends to grant patent...

Tags: Antares Pharma Inc., FDA, formulation, Government, U.S. Patent and Trademark Office
Roth Capital Partners 18th Annual Growth Stock Conference Presenter Profiles

- 2006-02-17

DANA POINT, Calif. -- Roth Capital Partners 18th Annual Growth Stock Conference takes place Feb. 20-22 at the St. Regis Monarch Beach Resort & Spa in Dana Point, Calif. For in-depth information about the event visit http://www.rothcp.com/index06%20DP.html. Below are profiles from Roth Capital Partners 18th Annual Growth Stock Conference...

Tags: Amerigon Inc., AMEX, Annual, Antares Pharma Inc., AspenBio Pharma Inc., AXT Inc., Bentley Pharmaceuticals Inc., Bodisen Biotech Inc., California, Clarient Inc., CollaGenex Pharmaceuticals Inc., Company, Delta Financial Corp., Diomed Holdings Inc., Emrise Corp., GeoPharma Inc., manufacturing, MedicalCV Inc., Merit Medical Systems Inc., Middleby Corp., MPA, Nasdaq Stock Market Inc., Neogen Corp., NetScout Systems Inc., network, Peregrine Pharmaceuticals Inc., stock, technology, Web, Zi Corp.
Techvest 7th Annual Healthcare Conference Presenter Profiles

- 2005-11-04

NEW YORK -- Techvest 7th Annual Healthcare Conference takes place 07 - 09 Nov. at the New York Palace Hotel in New York City. For in-depth information about the event visit http://www.rodmanandrenshaw.com/index.htm. Below are profiles from Techvest 7th Annual Healthcare Conference presenters. News releases, web cast advisories, and photos...

Tags: Aksys Ltd., Amex, Antares Pharma Inc., ArQule Inc., biotechnology, cell, Chelsea, Company, compound, CytRx Corp., Discovery Laboratories Inc., EntreMed Inc., FDA, Inyx Inc., MARKETING, MicroIslet Inc., molecule, Nasdaq Stock Market Inc., OrthoLogic Corp., Oxigene Inc., patient, phone, Solexa Inc., stem-cell, StemCells Inc., technology, therapy, VioQuest Pharmaceuticals Inc., Web

Rubicon Global Research Announces Investment Opinion: Rubicon Global Research, LLC is Initiating Coverage on Antares Pharma Inc., with a Speculative Strong-Buy Rating and a Near Term Price Target of $3.50

- 2005-09-06

PORTLAND, Ore. -- The Stock Exchange for Antares Pharma, Inc. should be AMEX sted NASDAQ. The corrected release reads: RUBICON GLOBAL RESEARCH ANNOUNCES INVESTMENT OPINION: RUBICON GLOBAL RESEARCH, LLC IS INITIATING COVERAGE ON ANTARES PHARMA INC., WITH A SPECULATIVE STRONG-BUY RATING AND A NEAR TERM PRICE TARGET OF...

Tags: Antares Pharma Inc., FINANCE, Investment, LLC, Nasdaq Stock Market Inc., Portland, Rubicon, stock

1

page 1 of 1

Decision Makers

Name (plus bio)	Position
Paul K Wotton PhD	President & Chief Executive Officer
Robert F Apple	Senior Vice President and Cfo
James E Hattersley	Vice President, Corporate Business Development
Lawrence M Christian	Vice President, Finance
Peter Sadowski	Vice President, Devices Group
Michael L Kasprick	Executive Director, Corporate Business Development
Dario Carrara	Director, Formulations Group

Board of Directors

Name (plus bio)	Position
Leonard S Jacob	Chairman
Jacques Gonella	Board of Directors

Organization	Position	Status
Antares Pharma, Inc.	President & Chief Executive Officer	Current
Genaera Corporation	Board of Directors	Current
Topigen Pharmaceuticals Inc	President and Chief Executive Officer	Former
Antares Real Estate Services	President	Former
Antares Real Estate Services	Chief Operating Officer	Former
Antares Pharma, Inc.	Chief Operating Officer	Former
Skyepharma, Inc.	Head of Global Business Development	Former
SkyePharma PLC	Head of Global Business Development	Former
Abbott Laboratories		Former
Penwest Pharmaceuticals, Co.		Former
University of Nottingham	PhD In Pharmaceutical Science	Former
Kingston Business School	MBA	Former
University of London	Bachelor in Pharmacy degree	Former

Organization	Position	Status
Antares Pharma, Inc.	Senior Vice President and Cfo	Current

Organization	Position	Status
Antares Pharma, Inc.	Vice President, Corporate Business Development	Current

Organization	Position	Status
Antares Pharma, Inc.	Vice President, Finance	Current

Organization	Position	Status
Antares Pharma, Inc.	Vice President, Devices Group	Current

Organization	Position	Status
Antares Pharma, Inc.	Executive Director, Corporate Business Development	Current

Organization	Position	Status
Antares Pharma, Inc.	Director, Formulations Group	Current

Organization	Position	Status
Pharmaderm	Director and Chairman of the Nominating and Corporate Governance Committee	Current
Antares Pharma, Inc.	Chairman	Current
Life Science Advisors, LLC	Chairman	Current
The Colon Cancer Alliance	Board Member	Current
The Recording Company	Director	Current
Jacob Internet Fund	Director	Current
Macromed, Inc.	Director	Current
Glyconix Corp	Board of Directors	Current
Quiqmeds, Inc.	Board of Directors	Current
The Colon Cancer Alliance	Chairman of the Board of Directors and Chief Executive Officer	Former
Genaera Corporation	Chief Operating Officer	Former
SmithKline Beecham Corporation	Worldwide Vice President	Former
Genaera Corporation	Co-Founder	Former
Temple University	Ph.D. In Pharmacology	Former
Medical College of Pennsylvania	M.D.	Former
GlaxoSmithKline Plc	member	Former

Organization	Position	Status
Antares Pharma, Inc.	Board of Directors	Current
Permatech, Inc.	Chairman	Former
Antares Pharma, Inc.	Chairman	Former

Executive News

Company and People Notes: Merck and Portola Sign Agreement; Eisai Appoints Senior Vice-Presidents; More ...

Pharmaceutical Technology - 8/26/09 - View Story
Antares Pharma Announces Launch of Tjet Needle-Free Injector

Business Wire via MSN Money - 8/25/09 - View Story
Antares Pharma Announces Launch of Tjet Needle-Free Injector System by Marketing Partner Teva

Business Wire - 8/25/09 - View Story
Antares Pharma Q2 net loss narrows

TradingMarkets - 8/14/09 - View Story
Antares Pharma Reports Second Quarter 2009 Financial and

Business Wire via MSN Money - 8/13/09 - View Story
Antares Pharma Reports Second Quarter 2009 Financial and Operating Results

RBC Dain Raushcer - 8/13/09 - View Story
Antares Pharma Welcomes Eamonn P. Hobbs to Board of Directors

Business Wire - 8/12/09 - View Story

AIS $1.14 -0.01 (-0.88% )

Intraday

|

3 Month

|

6 Month

|

1 Year

Average Volume	698,501
Shares Outstanding	81.71M
Market Cap	93.1M
Year High	1.31
Year Low	0.29
Earnings Per Share	-0.15
P/E Ratio	-7.60
Dividend	N/A
Yield	N/A

Industry Transcripts by Seeking Alpha

ZOLL Medical Corporation F4Q09 (Qtr End 27/09/09) Earnings Call Transcript
on Nov 11, 2009about ZOLL
RadNet, Inc. Q3 2009 Earnings Call Transcript
on Nov 09, 2009about RDNT
Cytori Therapeutics Q3 2009 Earnings Call Transcript
on Nov 09, 2009about CYTX
StoneMor Partners L.P. 3Q09 (Qtr End 9/30/09) Earnings Call Transcript
on Nov 09, 2009about STON
Sunrise Senior Living Inc Q3 2009 Earnings Call Transcript
on Nov 09, 2009about SRZ

Glass Door

Health Care Industry Companies

Company	Employer Rating
Kaiser Permanente	3.6
Boston Scientific	3.2
WellPoint	3.3
UnitedHealth Group	2.7
CIGNA	3.2

IndustryTop Rated

Your Work Five Ways to Speak Like Obama

Five Ways to Speak Like Obama

Barack Obama is a master at grabbing and keeping his audience's attention, which is the number one goal of any public speaker. How does he do it? Here are five key lessons from Obama's rhetorical playbook.
Your Industry Chicken War: KFC Appears to Be Plucking El Pollo Loco

Chicken War: KFC Appears to Be Plucking El Pollo Loco

In the highly publicized chicken wars, KFC seems to be winning the financial battle over El Pollo Loco. But is it really fair to compare the smaller chain to Colonel Sanders' empire?
Your Money 12 Tough Questions to Ask Your Parents

12 Tough Questions to Ask Your Parents

Talking with your parents about their estate is important to protect your family’s finances, but the conversation can be difficult at best. Here's what you need to ask and how to do it.